MA-BATTERY-VENTURES
15.9.2021 13:02:10 CEST | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, promoted software investor Jordan Welu to the role of partner and announced a dozen other internal promotions as it expands the global reach of its venture-capital and private-equity businesses worldwide. Battery is currently investing its 13th family of funds, raised in early 2020 and capitalized at a combined $2 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005299/en/
Welu, who joined Battery in 2014, is a B2B-tech investor who focuses on growth-stage and buyout investments in areas such as infrastructure software, cybersecurity and financial technology. He is currently involved with Battery portfolio companies Alogent, DomainTools, Forest2Market, Learnosity and Plixer. Previously, he backed Concurrent Real-Time (acquired by Spectris) and Enviance (acquired by Cority).
Prior to Battery, Welu, who is based in Boston, worked in software corporate development and finance at companies including Rogue Wave Software, a former Battery portfolio company, and Webroot. Earlier in his career, he worked in investment banking and equity research. Jordan is a graduate of Georgetown University.
Battery also named two existing team members to the role of principal: Roland Anderson, based in Boston, and Satoshi Harris-Koizumi, based in New York. Both specialize in software investments. Anderson joined Battery in 2014 and Harris-Koizumi in 2012.
There were also six promotions to vice president. These include Danel Dayan and Courtney Chow in Menlo Park; Mike Hoeksema and Viraj Parmar in New York; Lauren Wedell in Boston; and Lior Mallul in Herzliya, Israel. In addition, Battery promoted three team members to associate. These include Maximilian Jessen and Matt Klineman, based in Boston, and Diego Liranzo in New York. Earlier this year, Battery promoted Antonia Heiss, based in London, to associate. Finally, the firm announced it has hired Jenny Kang as the firm’s vice president of talent for venture- and growth-stage companies. Previously, Kang was the head of go-to-market executive recruiting at Sequoia Capital.
“Jordan’s promotion to partner, following his work with Concurrent Real-Time and Enviance, is richly deserved, as are the promotions of all the new principals, vice presidents and associates,” said Jesse Feldman, a Battery general partner who helped make the original investment in Welu’s previous employer Rogue Wave Software. “More broadly, the moves highlight Battery’s longtime preference for promoting talent from within the firm as we seek out the most promising technology investments regardless of stage, sector or geography. We’re also very excited to add Jenny Kang to our team as we continue to offer more value-added services, including recruiting and talent assistance, to our portfolio companies.”
In the last 12 months, Battery has seen seven of its portfolio companies—Affirm, Coinbase, Confluent, JFrog, Olo, Sprinklr and Sumo Logic—stage initial public offerings. Since its founding in 1983 through June 30 of this year, Battery has funded 468 companies, not including seed investments, and realized 185 M&A events and 69 IPOs in total.
About Battery Ventures
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005299/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
